title: LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
abstract: BACKGROUND
  Lysyl oxidase-like 2 (LOXL2) is a matrix-remodeling enzyme that has been shown to play a key role in invasion and metastasis of breast carcinoma cells. However, very little is known about its role in normal tissue homeostasis. Here, we investigated the effects of LOXL2 expression in normal mammary epithelial cells to gain insight into how LOXL2 mediates cancer progression.
  
  
  METHODS
  LOXL2 was expressed in MCF10A normal human mammary epithelial cells. The 3D acinar morphogenesis of these cells was assessed, as well as the ability of the cells to form branching structures on extracellular matrix (ECM)-coated surfaces. Transwell-invasion assays were used to assess the invasive properties of the cells. Clinically relevant inhibitors of ErbB2, lapatinib and Herceptin (traztuzumab), were used to investigate the role of ErbB2 signaling in this model. A retrospective study on a previously published breast cancer patient dataset was carried out by using Disease Specific Genomic Analysis (DSGA) to investigate the correlation of LOXL2 mRNA expression level with metastasis and survival of ErbB2-positive breast cancer patients.
  
  
  RESULTS
  Fluorescence staining of the acini revealed increased proliferation, decreased apoptosis, and disrupted polarity, leading to abnormal lumen formation in response to LOXL2 expression in MCF10A cells. When plated onto ECM, the LOXL2-expressing cells formed branching structures and displayed increased invasion. We noted that LOXL2 induced ErbB2 activation through reactive oxygen species (ROS) production, and ErbB2 inhibition by using Herceptin or lapatinib abrogated the effects of LOXL2 on MCF10A cells. Finally, we found LOXL2 expression to be correlated with decreased overall survival and metastasis-free survival in breast cancer patients with ErbB2-positive tumors.
  
  
  CONCLUSIONS
  These findings suggest that LOXL2 expression in normal epithelial cells can induce abnormal changes that resemble oncogenic transformation and cancer progression, and that these effects are driven by LOXL2-mediated activation of ErbB2. LOXL2 may also be a beneficial marker for breast cancer patients that could benefit most from anti-ErbB2 therapy.
authors: Joan
authors: J
authors: Chang
authors: Monica M
authors: MM
authors: Nicolau
authors: Thomas R
authors: TR
authors: Cox
authors: Daniel
authors: D
authors: Wetterskog
authors: John W M
authors: JW
authors: Martens
authors: Holly E
authors: HE
authors: Barker
authors: Janine T
authors: JT
authors: Erler
mesh_terms: D061354:Acinar Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D000594:Amino Acid Oxidoreductases / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D004847:Epithelial Cells / Q000378:metabolism; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D000077341:Lapatinib; D042361:Mammary Glands, Human / Q000378:metabolism / Q000473:pathology; D009024:Morphogenesis / Q000235:genetics; D009362:Neoplasm Metastasis; D010641:Phenotype; D011379:Prognosis; D011799:Quinazolines / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000594:Amino Acid Oxidoreductases; D000077341:Lapatinib; D011799:Quinazolines; D017382:Reactive Oxygen Species; D018719:Erb-b2 Receptor Tyrosine Kinases; C119091:LOXL2 protein, human
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Cancer Res. 2008 Jun 15;68(12):4541-50
references: 18559498
references: Cancer Res. 2002 Aug 1;62(15):4478-83
references: 12154058
references: Lancet. 2005 Feb 19-25;365(9460):671-9
references: 15721472
references: Mol Carcinog. 2007 Aug;46(8):624-8
references: 17477367
references: Nature. 2006 Apr 27;440(7088):1222-6
references: 16642001
references: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references: 12490681
references: Cell. 2009 Nov 25;139(5):891-906
references: 19931152
references: Mol Oncol. 2007 Jun;1(1):84-96
references: 18516279
references: Nat Med. 2010 Sep;16(9):1009-17
references: 20818376
references: Environ Health Perspect. 1989 Mar;80:71-83
references: 2647486
references: Oncogene. 2010 Nov 4;29(44):5883-94
references: 20697354
references: Oncogene. 2001 Nov 8;20(51):7551-62
references: 11709727
references: Prog Nucleic Acid Res Mol Biol. 2001;70:1-32
references: 11642359
references: Future Oncol. 2011 Jun;7(6):707-10
references: 21675833
references: Am J Pathol. 2006 Oct;169(4):1402-14
references: 17003495
references: Carcinogenesis. 2009 Oct;30(10):1660-9
references: 19625348
references: J Natl Cancer Inst. 2009 Jan 21;101(2):107-13
references: 19141783
references: Cancer Res. 2003 Apr 1;63(7):1657-66
references: 12670920
references: Int J Colorectal Dis. 2010 Mar;25(3):303-11
references: 20012301
references: Mol Cell. 2012 May 11;46(3):369-76
references: 22483618
references: Cell Death Differ. 2011 Sep;18(9):1470-7
references: 21617693
references: Nat Med. 2012 Mar 04;18(4):529-37
references: 22388088
references: Methods. 2003 Jul;30(3):256-68
references: 12798140
references: Ann Oncol. 2002 Nov;13(11):1743-8
references: 12419746
references: EMBO J. 2005 Oct 5;24(19):3446-58
references: 16096638
references: Mol Biol Rep. 2011 Jan;38(1):145-9
references: 20306300
references: Genes Chromosomes Cancer. 2007 Jul;46(7):644-55
references: 17394133
references: Breast Cancer Res. 2004;6(1):1-11
references: 14680479
references: J Biol Chem. 2000 Mar 17;275(11):8027-31
references: 10713122
references: Int J Cancer. 2009 Jul 15;125(2):318-27
references: 19330836
references: Nat Rev Cancer. 2012 Jul 19;12(8):540-52
references: 22810810
references: BMC Cancer. 2007 Sep 25;7:182
references: 17894856
references: Cancer Res. 1990 Sep 15;50(18):6075-86
references: 1975513
references: Clin Exp Metastasis. 2009;26(1):35-49
references: 18814043
references: EMBO Mol Med. 2011 Sep;3(9):528-44
references: 21732535
references: Nat Cell Biol. 2001 Sep;3(9):785-92
references: 11533657
references: Cell Mol Life Sci. 2004 Jan;61(2):192-208
references: 14745498
references: Cancer Res. 2011 Mar 1;71(5):1561-72
references: 21233336
references: Oncogene. 2010 Dec 9;29(49):6485-98
references: 20802523
references: J Neurosci. 1997 Nov 1;17(21):8293-9
references: 9334404
references: PLoS One. 2012;7(6):e38773
references: 22701711
references: PLoS One. 2012;7(12):e51786
references: 23251624
references: Anal Biochem. 2002 Jan 15;300(2):245-51
references: 11779117
references: Biochim Biophys Acta. 2003 Apr 11;1647(1-2):220-4
references: 12686136
references: Nat Rev Cancer. 2005 Sep;5(9):675-88
references: 16148884
references: Cancer Cell. 2005 Sep;8(3):241-54
references: 16169468
references: J Hepatol. 2005 Sep;43(3):499-507
references: 16023247
references: Cold Spring Harb Perspect Biol. 2009 Jul;1(1):a000513
references: 20066074
references: Semin Cancer Biol. 2010 Jun;20(3):139-45
references: 20452434
references: Oncogene. 2012 Aug 2;31(31):3569-83
references: 22139081
references: Bioinformatics. 2007 Apr 15;23(8):957-65
references: 17277331
references: Mol Cell Biol. 2005 Jun;25(11):4591-601
references: 15899862
references: Cancer Lett. 2009 Mar 18;275(2):227-33
references: 19022565
references: Mol Cell Biol. 1999 Oct;19(10):6845-57
references: 10490623